Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,861 matching trials from the live ClinicalTrials.gov search.
Filters: Chapel Hill, North Carolina Clear all
Recruiting No phase listed Observational

Rare and Atypical Diabetes Network

NCT05544266
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus Progression, Glucose Intolerance, Glucose Metabolism Disorders, Metabolic Disease, Endocrine; Complications, Endocrine System Diseases
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 31, 2026, 10:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

NCT00448357
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, methotrexate
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 31, 2026, 10:35 AM EDT
Completed No phase listed Observational

Genetic Architecture of Avoidant/Restrictive Food Intake Disorder

NCT05605067
View directory record Official record
Conditions
ARFID, Eating Disorders, Eating Disorders in Children, Eating, Picky
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
7 Years to 99 Years
Enrollment
5,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 31, 2026, 10:35 AM EDT
Completed Not applicable Interventional

Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx

NCT03418792
View directory record Official record
Conditions
Head and Neck Cancer, Oropharynx Cancer, Xerostomia Due to Radiotherapy
Interventions
Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 31, 2026, 10:35 AM EDT
Completed No phase listed Observational

Stem Cell Related Donor Safety Study

NCT00948636
View directory record Official record
Conditions
Related Hematopoietic Stem Cell Donors
Interventions
Not listed
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
Not listed
Enrollment
1,812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
52
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 31, 2026, 10:35 AM EDT
Completed No phase listed Observational

Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort

NCT02897271
View directory record Official record
Conditions
Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Colitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Little Rock, Arkansas • Denver, Colorado • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 31, 2026, 10:35 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Making Effective Human Papillomavirus (HPV) Vaccine Recommendations

NCT02377843
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Participatory, Efficient
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 31, 2026, 10:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Care2BWell: Worksite Wellness for Child Care

NCT02381938
View directory record Official record
Conditions
Physical Activity
Interventions
Healthy Lifestyles, Healthy Finances
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 31, 2026, 10:35 AM EDT
Completed No phase listed Observational

Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer

NCT00068328
View directory record Official record
Conditions
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years and older · Female only
Enrollment
1,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
85
States / cities
Mountain View, California • Palo Alto, California • Pismo Beach, California + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 31, 2026, 10:35 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

NCT00381706
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cetuximab, ECF, IC, FOLFOX
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
227
States / cities
Norwalk, Connecticut • Lewes, Delaware • Newark, Delaware + 158 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 31, 2026, 10:35 AM EDT
Completed Phase 2Phase 3 Interventional Results available

SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study

NCT02778867
View directory record Official record
Conditions
Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis (EoE)
Interventions
1 Food Elimination Diet Therapy, 6 Food Elimination Diet Therapy, 6 Food Elimination Diet (after 1FED failure), Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
Other · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 60 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 31, 2026, 10:35 AM EDT
Completed Phase 2 Interventional Results available

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

NCT01085214
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Laboratory Biomarker Analysis, Selumetinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 31, 2026, 10:35 AM EDT
Terminated Phase 2Phase 3 Interventional

Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer

NCT00034333
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
MTC-DOX for Injection
Drug
Lead sponsor
FeRx
Industry
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
11
States / cities
Long Beach, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 10:35 AM EDT
Completed Phase 3 Interventional Results available

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

NCT01224171
View directory record Official record
Conditions
Crohn's Disease
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
40
States / cities
Lafayette, Colorado • Hamden, Connecticut • Gainesville, Florida + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 31, 2026, 10:35 AM EDT
Completed Not applicable Interventional Results available

Open Trial of a Behavioral Activation Telepsychology Intervention for People Who Inject Drugs

NCT04943432
View directory record Official record
Conditions
Intravenous Drug Usage
Interventions
Behavioral Activation
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Oct 31, 2026, 10:35 AM EDT
Active, not recruiting Phase 2 Interventional

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

NCT03012321
View directory record Official record
Conditions
Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Olaparib, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Completed Not applicable Interventional

Mindfulness Intervention in Young Adults With a Concussion History

NCT05399849
View directory record Official record
Conditions
Concussion, Brain, Concussion Post Syndrome
Interventions
Mindfulness Exercises and Meditations
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 31, 2026, 10:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

NCT07226895
View directory record Official record
Conditions
Clinical High Risk for Psychosis (CHR)
Interventions
MT1988 Low Dose, MT1988 High Dose, Placebo
Drug
Lead sponsor
Monument Therapeutics Limited
Industry
Eligibility
17 Years to 30 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rethinking Eating and FITness for Men

NCT01843595
View directory record Official record
Conditions
Weight Loss, Overweight
Interventions
REFIT Intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Oct 31, 2026, 10:35 AM EDT
Recruiting No phase listed Observational

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

NCT06218875
View directory record Official record
Conditions
AAA - Abdominal Aortic Aneurysm
Interventions
Not listed
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
45
States / cities
Little Rock, Arkansas • Irvine, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Completed Phase 3 Interventional Results available

Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System

NCT01401361
View directory record Official record
Conditions
Typical Atrial Flutter
Interventions
Treatment Arm
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Birmingham, Alabama • Denver, Colorado • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 31, 2026, 10:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study on the Effect of High-Calorie Infant Formula on Growth and Nutrition in HIV-Infected Infants

NCT00000873
View directory record Official record
Conditions
HIV Infections
Interventions
Infant Formula
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 17 Days
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
62
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Oct 31, 2026, 10:35 AM EDT
Completed Not applicable Interventional

Food and Friends: Healthy Meals Delivered to You

NCT06415370
View directory record Official record
Conditions
Mental Health Issue, Food Insecurity
Interventions
Home Delivered Healthy Meals, In-person "friendly visits", Student Companion calls
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 31, 2026, 10:35 AM EDT